Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued on Friday. The firm set a “hold” rating on the medical research company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a report on Tuesday.

Cytosorbents Trading Down 7.1 %

Cytosorbents stock opened at $0.81 on Friday. Cytosorbents has a 1 year low of $0.78 and a 1 year high of $4.29. The firm’s 50-day moving average is $0.90 and its 200-day moving average is $1.11. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.51 and a current ratio of 1.77. The company has a market cap of $43.99 million, a P/E ratio of -1.27 and a beta of 0.62.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. Cytosorbents had a negative net margin of 78.43% and a negative return on equity of 120.24%. The firm had revenue of $8.67 million for the quarter, compared to analysts’ expectations of $9.29 million. On average, equities analysts expect that Cytosorbents will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CTSO. Raymond James & Associates bought a new stake in shares of Cytosorbents during the fourth quarter valued at approximately $56,000. Skylands Capital LLC raised its stake in Cytosorbents by 10.5% during the 4th quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock valued at $3,612,000 after acquiring an additional 309,543 shares in the last quarter. Chicago Partners Investment Group LLC boosted its position in Cytosorbents by 84.0% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 36,358 shares of the medical research company’s stock worth $67,000 after acquiring an additional 16,598 shares during the period. Sargent Investment Group LLC grew its stake in shares of Cytosorbents by 4.1% in the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after purchasing an additional 51,699 shares in the last quarter. Finally, Key Client Fiduciary Advisors LLC increased its holdings in shares of Cytosorbents by 188.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 22,557 shares during the period. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.